aktiencheck.de - Forum - Theriva Biologics Inc

Was war das?

letzte News war gut, [mehr]

Synthetic Biologics SYN

Nochmal die Frage, Hatte jemand Adeona zu dem Zeitpunkt(20.2.),als sie in Synthetic Biologics umgetauscht wurden? Wäre wirklich wichtig,wenn er oder sie sich bei mir melden würde. [mehr]

Klein,aber fein: Adeona Pharmaceuticals

Adeona vs Astex, Hey leute,Adeona scheint grundlos heissgelaufen,es bietet sich eine erstklassige chance in die weitaus interessantere Astex umzuschichten,die heute sogar noch mal 22% billiger geworden ist ich habe einen Thread zu Astex aufgemacht ! Adeona Pharmaceuticals My only concern for Adeona is knowing that the recent run was accompanied by modest company news, and after watching Adeona run, fall, and now running again, I'm left to wonder: Is this real? Or is this just deep pockets taking advantage of a good situation? I don't mean to sound pessimistic, but more than one quality firm has been hurt by the Market's unexplainable 'run' then 'dump', especially in the age of computer flash-crashes. Or for excited long-investors who finally see their investment going up and wake up the next morning to read that the company is diluting shares or selling equity securities but this of course is due to the company's new direction with Intrexon Corporation. I am scratching my head [mehr]

Adeona Pharma ( WKN: A0RBK9 / AEN ) // AMEX

News sieht ja ganz gut aus, Adeona Announces Completion of 50% Enrollment in Part 2 of CopperProof-2 Study in Alzheimer's Disease and Mild Cognitive Impairment Subjects ANN ARBOR, Mich., June 7 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN) announced the completion of 50% enrollment in Part 2 of its clinical study, A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease (CopperProof-2). The CopperProof-2 study represents the first controlled clinical study of oral zinc cysteine for the dietary management of Alzheimer's disease and mild cognitive impairment. Part 2 of the CopperProof-2 study is designed as a 60-subject comparator study. Subjects are randomized on a 50:50 basis to receive either Zinthionein ZC or matching placebo. After 3 and 6 months on clinical trial material, serum measurements of zinc and copper are taken, and any changes in cognitive function using standard clinical tests used in Al [mehr]